Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

2.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
3.
4.

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP.

J Clin Psychiatry. 2005 Oct;66(10):1270-8.

PMID:
16259540
5.

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.

Davidson JR, Bose A, Korotzer A, Zheng H.

Depress Anxiety. 2004;19(4):234-40.

PMID:
15274172
7.
8.
9.

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

Burke WJ, Gergel I, Bose A.

J Clin Psychiatry. 2002 Apr;63(4):331-6.

PMID:
12000207
10.

Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study.

Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM.

J Clin Psychiatry. 2003 Jul;64(7):785-92.

PMID:
12934979
11.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
12.

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

Stahl SM, Gergel I, Li D.

J Clin Psychiatry. 2003 Nov;64(11):1322-7.

PMID:
14658946
13.

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD.

J Clin Psychiatry. 2002 Jan;63(1):66-74.

PMID:
11838629
14.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
15.
16.

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.

Stein DJ, Versiani M, Hair T, Kumar R.

Arch Gen Psychiatry. 2002 Dec;59(12):1111-8.

PMID:
12470127
17.

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.

Lepola UM, Loft H, Reines EH.

Int Clin Psychopharmacol. 2003 Jul;18(4):211-7.

PMID:
12817155
18.

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.

Lepola U, Wade A, Andersen HF.

Int Clin Psychopharmacol. 2004 May;19(3):149-55. Erratum in: Int Clin Psychopharmacol. 2004 Jul;19(4):255.

PMID:
15107657
19.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
20.

Controlled-release paroxetine in the treatment of patients with social anxiety disorder.

Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L.

J Clin Psychiatry. 2004 Feb;65(2):222-9.

PMID:
15003077

Supplemental Content

Support Center